MMP Inhibitor For Orofacial Pain

描述(申请人提供)：Aquilus制药公司提议评估一种新的基质金属蛋白酶(MMP)抑制剂对脊髓和口面部神经病理性疼痛的动物行为模型的影响。第一阶段的目标是扩大该抑制剂的合成，确定其药代动力学(PK)，然后在脊神经结扎(SNL)-小鼠和大鼠三叉神经病理性疼痛动物模型上进行动物疗效研究。这项拟议工作的最终目标是评估是否可以开发一种基质金属蛋白酶抑制剂来治疗慢性口腔面部疼痛。 公共卫生相关性：Aquilus制药公司将评估一种针对一组酶的抑制剂，这些酶最近被发现与神经病理性疼痛的病理有关。Aquilus将在各种动物疼痛模型中测试这种抑制剂，特别强调治疗慢性口腔面部疼痛。如果该项目成功，Aquilus制药公司将能够进一步开发这种新的抑制剂，作为治疗口腔面部疼痛的一流药物，而不会有任何令人上瘾或兴奋的副作用。

DESCRIPTION (provided by applicant): Aquilus Pharmaceuticals, Inc. proposes to evaluate the effects of a novel matrix metalloproteinase (MMP) inhibitor on animal behavioral models of spinal and orofacial neuropathic pain. The goals for Phase I are to scale-up the synthesis of the inhibitor, determine its pharmacokinetics (PK) and then run animal efficacy studies in both the spinal nerve ligation (SNL)- mouse and rat trigeminal neuropathic pain animal models. The ultimate goal of the proposed work is to evaluate whether a matrix metalloproteinase inhibitor can be developed for the treatment of chronic orofacial pain. PUBLIC HEALTH RELEVANCE: Aquilus Pharmaceuticals will evaluate an inhibitor to a group of enzymes that that have recently been discovered to be involved in the pathology of neuropathic pain. Aquilus will test this inhibitor in various animal pain models with a special emphasis on the treatment of chronic orofacial pain. If the project is successful, Aquilus Pharmaceuticals will be able to further develop this new inhibitor as a first in class treatment for orofacial pain without having any addictive or euphoric side effects.